Jonathan Biller Biography and Net Worth

Jonathan has deep legal, industry and business experience and expertise that will support our continued growth. He joined Vertex in 2022 and serves on the Executive Committee and oversees all aspects of our global legal and compliance functions.

Her earned his bachelor’s degree in history from Brown University and his law degree from Yale Law School. Prior to Vertex, Jonathan served in several executive roles at Agios Pharmaceuticals, including Chief Legal Officer and most recently Chief Financial Officer and Head of Corporate Affairs. Prior to this, he served as Executive Vice President, General Counsel at Celgene, where he was responsible for its global legal function, and before that as Senior Vice President, Tax and Treasury. Prior to Celgene, he served in various leadership roles at Bunge Limited and Alcon, Inc. He began his legal career at Hopkins & Sutter, rising to the level of partner, and was also partner at Foley & Lardner after the firms merged.

What is Jonathan Biller's net worth?: The estimated net worth of Jonathan Biller is at least $4.20 million as of October 2nd, 2023. Mr. Biller owns 10,569 shares of Vertex Pharmaceuticals stock worth more than $4,198,747 as of December 22nd. This net worth approximation does not reflect any other assets that Mr. Biller may own. Learn More about Jonathan Biller's net worth.
How old is Jonathan Biller?: Mr. Biller is currently 60 years old. There are 6 older executives and no younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals is Dr. Jeffrey Marc Leiden M.D., Ph.D., Executive Chairman, who is 68 years old. Learn More on Jonathan Biller's age.
How do I contact Jonathan Biller?: The corporate mailing address for Mr. Biller and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Jonathan Biller's contact information.
Has Jonathan Biller been buying or selling shares of Vertex Pharmaceuticals?: Jonathan Biller has not been actively trading shares of Vertex Pharmaceuticals during the past quarter. Most recently, Jonathan Biller sold 610 shares of the business's stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $346.76, for a transaction totalling $211,523.60. Following the completion of the sale, the executive vice president now directly owns 10,569 shares of the company's stock, valued at $3,664,906.44. Learn More on Jonathan Biller's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Jonathan Biller Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/2/2023	Sell	610	$346.76	$211,523.60	10,569

Jonathan Biller Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $397.27

$386.49

$401.31

50 Day Range

MA: $470.41

$396.64

$516.74

2 Week Range

Now: $397.27

$377.85

$519.88

Volume

6,202,268 shs

Average Volume

1,238,190 shs

Market Capitalization

$102.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

Jonathan Biller Biography and Net Worth

What is Jonathan Biller's net worth?

How old is Jonathan Biller?

How do I contact Jonathan Biller?

Has Jonathan Biller been buying or selling shares of Vertex Pharmaceuticals?

Who are Vertex Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Vertex Pharmaceuticals?